한글목차

듀센형 근이영양증(DMD) 치료제 시장 규모는 최근 급격하게 확대하고 있습니다. 2025년 163억 8,000만 달러에서 2026년에는 214억 3,000만 달러로, CAGR 30.8%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 듀센형 근이영양증 발병률 증가, 의료진의 인식 개선, 초기 단계의 임상시험 시작, 물리치료 및 지지요법의 보급 확대, 희귀질환 치료에 대한 정부의 지원책 등에 기인하는 것으로 보입니다.

듀센형 근이영양증(DMD) 치료제 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 621억 3,000만 달러에 달하고, CAGR은 30.5%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 유전자 치료의 발전, 정밀의료에 대한 투자 확대, 환자 모니터링의 기술 통합, 생물학적 제제 제조의 확대, 제약회사와 생명공학 기업 간의 협력 강화 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 맞춤형 치료 개발, 유전자 편집 및 유전자 치료의 발전, 새로운 약물전달 시스템, 희귀질환 치료제 시장 확대, 환자 중심 치료 모델 등이 있습니다.

임상시험의 증가는 향후 몇 년 동안 듀센형 근이영양증(DMD) 치료제 시장의 성장을 견인할 것으로 예상됩니다. 임상시험은 새로운 의료 절차, 중재 또는 약물의 안전성, 유효성, 잠재적 이점을 평가하기 위해 인간을 대상으로 시행하는 연구입니다. 미충족 수요에 대응하는 혁신적인 치료법에 대한 수요가 증가함에 따라 임상시험의 수는 증가하는 추세입니다. 듀센형 근이영양증(DMD) 치료제는 임상시험을 통해 질병 진행 지연 및 환자의 근육 기능 개선 능력을 평가합니다. 예를 들어, 미국 정부 기관인 국립의학도서관(NLM)이 2025년 4월에 발표한 자료에 따르면, 2023년 2,7,751건의 중재적 임상시험이 시작되었습니다. 따라서 임상시험의 증가가 듀센형 근이영양증(DMD) 치료제 시장의 성장을 견인하고 있습니다.

듀센형 근이영양증(DMD) 치료제 시장의 주요 기업들은 DMD 환자의 치료 효과와 접근성을 개선하고 시장에서의 입지를 유지하기 위해 새로운 기술을 도입하고 있습니다. 예를 들어, 2023년 7월 영국에 본사를 둔 합성생물학 기업 비트바이오(Bit Bio Ltd.)는 듀센형 근이영양증(DMD) 치료의 진전을 목표로 하는 질병 모델 제품을 발표했습니다. 'ioSkeletal Myocytes DMD Exon 44 Deletion' 및 'ioSkeletal Myocytes DMD Exon 52 Deletion'으로 명명된 이들 질환 모델은 디스트로핀 단백질 생산을 담당하는 유전자에 유전공학적으로 결손을 도입한 인간 골격근 세포입니다. 비트바이오의 모델은 인공만능줄기세포(iPS 세포)에서 재프로그래밍된 것으로, 연구용 인간 세포의 안정적이고 확장 가능한 공급원을 제공합니다. 이를 통해 1차 세포의 가변성과 조달에 대한 문제를 해결합니다. 이러한 모델은 질병 메커니즘과 잠재적 치료법에 대한 지식을 제공함으로써 DMD 치료법 개발을 지원하고, 효과적인 치료법을 찾는 연구자들의 노력을 가속화할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Duchenne muscular dystrophy (DMD) therapeutics refer to medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder marked by progressive muscle weakness and degeneration. These therapies are intended to slow disease progression, improve muscle function, and enhance the overall quality of life for individuals with duchenne muscular dystrophy.

The main types of duchenne muscular dystrophy (DMD) therapeutics include small molecules and biologics. Small molecules are low-molecular-weight compounds that interact with specific proteins or targets in the body and can be designed to address particular aspects of DMD, such as reducing inflammation, promoting muscle regeneration, or targeting specific genetic mutations. These therapeutics are distributed through offline and online channels and are used in applications such as hospitals, clinics, and home care.

Tariffs have influenced the duchenne muscular dystrophy therapeutics market by increasing the cost of imported raw materials, biologics, and gene therapy components, thereby affecting production timelines and drug pricing. Regions like North America and Europe, which rely on global supply chains for advanced biologics, are most impacted, while segments like gene therapies and protein replacement therapies face higher cost pressures. However, tariffs have also prompted manufacturers to diversify sourcing, localize production, and innovate more cost-efficient therapeutic solutions, potentially strengthening regional capabilities over time.

The duchenne muscular dystrophy (dmd) therapeutics market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy (dmd) therapeutics market statistics, including duchenne muscular dystrophy (dmd) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (dmd) therapeutics market share, detailed duchenne muscular dystrophy (dmd) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy (dmd) therapeutics industry. This duchenne muscular dystrophy (dmd) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (dmd) therapeutics market size has grown exponentially in recent years. It will grow from $16.38 billion in 2025 to $21.43 billion in 2026 at a compound annual growth rate (CAGR) of 30.8%. The growth in the historic period can be attributed to rising prevalence of duchenne muscular dystrophy, increased awareness among healthcare providers, early-stage clinical trials initiation, growing adoption of physiotherapy and supportive care, government incentives for rare disease treatments.

The duchenne muscular dystrophy (dmd) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $62.13 billion in 2030 at a compound annual growth rate (CAGR) of 30.5%. The growth in the forecast period can be attributed to advances in gene therapy, growing investment in precision medicine, technological integration in patient monitoring, expansion of biologics manufacturing, increased collaboration between pharma and biotech companies. Major trends in the forecast period include personalized therapeutic development, gene editing and gene therapy advancements, novel drug delivery systems, orphan drug market expansion, patient-centric care models.

The increasing number of clinical trials is expected to drive the growth of the Duchenne muscular dystrophy (DMD) therapeutics market in the coming years. Clinical trials are research studies conducted on human participants to assess the safety, efficacy, and potential benefits of new medical treatments, interventions, or drugs. The number of clinical trials is rising due to growing demand for innovative therapies that address unmet medical needs. Duchenne muscular dystrophy (DMD) therapeutics are evaluated in clinical trials to determine their ability to slow disease progression and improve muscle function in patients. For instance, in April 2025, the National Library of Medicine (NLM), a US-based government agency, reported that 27,751 interventional clinical trials were initiated in 2023. Therefore, the rising number of clinical trials is driving growth in the Duchenne muscular dystrophy (DMD) therapeutics market.

Major companies in the Duchenne muscular dystrophy (DMD) therapeutics market are adopting new technologies to enhance the effectiveness and accessibility of treatments for DMD patients and maintain their market position. For instance, in July 2023, Bit Bio Ltd., a UK-based synthetic biology company, launched disease model products to advance Duchenne muscular dystrophy (DMD) treatments. The disease models, named ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes with genetically engineered deletions in the gene responsible for dystrophin protein production. Bit Bio's models, reprogrammed from induced pluripotent stem cells (iPSCs), provide a consistent and scalable source of human cells for research, addressing challenges related to variability and sourcing of primary cells. These models support the development of DMD treatments by offering insights into disease mechanisms and potential therapies, potentially accelerating the work of researchers seeking effective therapies for DMD.

In November 2024, Novartis AG, a Switzerland-based pharmaceuticals company, acquired Kate Therapeutics Inc. for $1.1 billion. Through this acquisition, Novartis aimed to expand its neuromuscular disease portfolio by integrating Kate's preclinical AAV-based gene therapy programs targeting Duchenne muscular dystrophy (DMD) and other muscle disorders. Kate Therapeutics is a US-based biotechnology company specializing in next-generation gene therapy candidates for DMD using novel capsid and gene regulation technologies.

Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Exonics Therapeutics Inc., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc., Ultragenyx Pharmaceutical Inc.

North America was the largest region in the DMD therapeutics market in 2025. The regions covered in the duchenne muscular dystrophy (dmd) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy (dmd) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses duchenne muscular dystrophy (dmd) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy (dmd) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy (dmd) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Small Molecules; Biologics
• 2) By Distribution Channel: Offline; Online
• 3) By Application: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Small Molecules: Exon Skipping Therapies; Antisense Oligonucleotides; Read-Through Compounds
• 2) By Biologics: Gene Therapies; Cell Therapies; Protein Replacement Therapies
• Companies Mentioned: BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Exonics Therapeutics Inc.; Wave Life Sciences Ltd.; MeiraGTx Holdings plc; Editas Medicine Inc.; Solid Biosciences Inc.; Santhera Pharmaceuticals Holding; Avidity Biosciences LLC; ReveraGen BioPharma Inc.; Capricor Therapeutics Inc.; Dynacure S.A.; Summit Therapeutics plc; CRISPR Therapeutics AG; Akouos Inc.; Audentes Therapeutics Inc.; Stoke Therapeutics Inc.; Astellas Pharma Inc.; Translate Bio Inc.; Ultragenyx Pharmaceutical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Therapeutic Development
  • 4.2.2 Gene Editing And Gene Therapy Advancements
  • 4.2.3 Novel Drug Delivery Systems
  • 4.2.4 Orphan Drug Market Expansion
  • 4.2.5 Patient-Centric Care Models

5. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Home Care Providers
• 5.4 Specialty Treatment Centers
• 5.5 Research Institutes

6. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

• 9.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecules, Biologics
• 9.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Offline, Online
• 9.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Home Care
• 9.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
• 9.5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gene Therapies, Cell Therapies, Protein Replacement Therapies

10. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional And Country Analysis

• 10.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 11.1. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 12.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 13.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 14.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 15.1. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 16.1. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 17.1. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 18.1. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 19.1. South East Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 20.1. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 21.1. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 22.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 23.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 24.1. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 25.1. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 26.1. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 27.1. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 28.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 29.1. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 30.1. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 31.1. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 32.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 33.1. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 34.1. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regulatory and Investment Landscape

36. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Company Profiles
  • 36.3.1. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Exonics Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Wave Life Sciences Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Other Major And Innovative Companies

• MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc.

38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

40. Duchenne Muscular Dystrophy (DMD) Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer